Latest news
25 items- FDAFDA Approval for TAZVERIK issued to EPIZYME INCSubmission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling
- FDAFDA Approval for TAZVERIK issued to EPIZYME INCSubmission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling
- 13D/GSEC Form SC 13G/A filed by Epizyme Inc. (Amendment)SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
- NEWSLooking Into Epizyme's Return On Capital EmployedAccording to Benzinga Pro data, during Q2, Epizyme (NASDAQ:EPZM) posted sales of $27.53 million. Earnings were up 35.6%, but Epizyme still reported an overall loss of $35.74 million. In Q1, Epizyme brought in $8.70 million in sales but lost $55.51 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Epizyme posted an ROCE of 1.76%
- SECSEC Form 15-12G filed by Epizyme Inc.15-12G - Epizyme, Inc. (0001571498) (Filer)
- SECSEC Form EFFECT filed by Epizyme Inc.EFFECT - Epizyme, Inc. (0001571498) (Filer)
- SECSEC Form EFFECT filed by Epizyme Inc.EFFECT - Epizyme, Inc. (0001571498) (Filer)
- SECSEC Form EFFECT filed by Epizyme Inc.EFFECT - Epizyme, Inc. (0001571498) (Filer)
- INSIDERSEC Form 4: Giordano Michael F returned 17,054 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Goldfischer Carl returned 3,403,005 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Conroy Kevin T returned 62,318 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Richon Victoria returned 22,608 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Mott David M returned 8,994 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Beveridge, Roy A returned 46,037 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Agarwal Shefali returned 286,539 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4 filed by Legorreta Pablo G.4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4 filed by Korn Jerald4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Beaulieu Joseph returned 52,076 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Bate Kenneth returned 17,054 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Kutok Jeffery returned 120,067 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Stuckley Carol returned 25,696 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- INSIDERSEC Form 4: Bogle Grant C. returned 259,170 shares to the company, closing all direct ownership in the company4 - Epizyme, Inc. (0001571498) (Issuer)
- SECSEC Form S-8 POS filed by Epizyme Inc.S-8 POS - Epizyme, Inc. (0001571498) (Filer)
- SECSEC Form S-8 POS filed by Epizyme Inc.S-8 POS - Epizyme, Inc. (0001571498) (Filer)
- SECSEC Form POS AM filed by Epizyme Inc.POS AM - Epizyme, Inc. (0001571498) (Filer)
EPZM FAQ
7 questionsWhat does Epizyme Inc. do?
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as...Where does EPZM stock trade?
Epizyme Inc. (EPZM) is listed on NASDAQ.What sector and industry is EPZM in?
Epizyme Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Epizyme Inc. go public?
Epizyme Inc. (EPZM) completed its IPO in 2013.What are analysts saying about EPZM?
Epizyme Inc. has had 5 recent analyst actions on file. The most recent action was from Cowen: Market Perform with a $150.00 price target on 2022-06-28.What companies are similar to EPZM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EPZM side-by-side with any of them on Quantisnow.How can I track EPZM on Quantisnow?
Quantisnow aggregates Epizyme Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EPZM to receive live email and push alerts on every new disclosure.